Neuromyelitis Optica associated Optic Neuritis
Conditions
Interventions
1:Intravenous 100mg Rituximab, 1/week*4
2:Oral azathioprine (2.5-3 mg/kg bodyweight/day) or mycophenolate mofetil (1000-1500mg/day)
Sponsors
The Ophthalmology Department of the Chinese Peoples Liberation Army Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for NMO-ON (fulfill one of following criteria: (1) Meet the Wingerchuk 2006 diagnostic criteria for NMO; (2) Recurrent ON or first-episode bilateral simultaneous ON meeting the ONTT diagnostic criteria for ON, andwith positive AQP4-Ab and/or NMO-IgG in blood and/or cerebral-spinal fluid, testing by both cell-based assay andenzyme-linked immunosorbent assay); 2. Aged from 18 to 70 years; 3. Agreed with the protocol for this study andsigned informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Allergic to Rituximab or mouse protein; 3. Abnormal cardiovascular, liver, or hematopoietic function; patients with diabetes or blood pressure >140/90 mmHg; 4. The medication of other disease mediated treatment (interferon, natalizumab, FTY-720, etc.) within 6 months; 5. Participant in other clinical trials; 6. Severe mental or language disorder; 7. Other inadvisable reasons for this research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EDSS score;Best Corrected Visual Acuity;Annual Relapse Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual Field;Visual Evoked Potential;Para-Optic Disc andMacular Retinal Nerve Fiber Layer Thickness (Optical Coherence Tomography);Length of Spinal Lesion (Magnetic Resonance Imaging); | — |
Countries
China
Contacts
Public ContactShihui Wei
Outcome results
None listed